Home › Calculator › SNPHY Dividend Calculator 2026
SNPHY Dividend DRIP Calculator 2026
1.38% YieldHealthcareSanten Pharmaceutical Co., Ltd. · OTC
Price: $13.90 · Annual div: $0.19/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When SNPHY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your SNPHY snowball 📈
$10,000 in SNPHY → $691.2K in 10 years · $564.56/month
About Santen Pharmaceutical Co., Ltd. (SNPHY) — Dividend Analysis 2026
Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains a significant pipeline and array of products focused on ophthalmic conditions. For glaucoma and ocular hypertension, their drug candidates encompass DE-111, currently undergoing Phase III clinical evaluation; DE-117, which is available in Japan; DE-126, now in Phase IIb trials; DE-128, being developed for European markets and also in Phase II/III trials within the United States; and DE-130A, another compound advancing through Phase III clinical trials. Santen's development efforts also extend to treatments for other eye ailments: DE-114A for allergic conjunctivitis, DE-076C to address vernal keratoconjunctivitis, and DE-109, a therapy for uveitis that is in Phase III trials. Furthermore, their initiatives against myopia include DE-127, which is simultaneously in Phase II/III clinical trials in Japan and Phase III across Asia, alongside STN1013400, currently in its initial Phase I clinical trials for the same condition. They also offer DE-089C, a treatment for dry eye that has successfully completed its Phase III clinical trials. Beyond prescription medications, Santen also supplies a selection of over-the-counter pharmaceutical products. The corporation, founded in Osaka, Japan, in 1890, was initially known as Santendo Pharmaceutical Co., Ltd. before formally adopting its current name, Santen Pharmaceutical Co., Ltd., in 1958.
Compare SNPHY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full SNPHY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SNPHY position with:
🌍 SNPHY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SNPHY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.38% | -1.42% | $138 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.17% | -1.63% | $117 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.10% | -1.70% | $110 / yr |
| 🇬🇧 UK ISA | 0% | 1.38% | -1.42% | $138 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.26% | -1.54% | $126 / yr |
| 🇨🇦 TFSA | 0% | 1.38% | -1.42% | $138 / yr |
| 🇨🇦 CA Taxable | 25% | 1.03% | -1.76% | $104 / yr |
| 🇦🇺 Super (pension) | 15% | 1.17% | -1.63% | $117 / yr |
| 🇦🇺 AU Taxable | 30% | 0.97% | -1.83% | $97 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.02% | -1.78% | $102 / yr |
| 🇫🇷 FR Taxable | 30% | 0.97% | -1.83% | $97 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SNPHY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.19/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SNPHY Dividend Payment Schedule
SNPHY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 SNPHY vs Healthcare Benchmarks
How SNPHY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SNPHY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SNPHY Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SNPHY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Santen Pharmaceutical Co., Ltd. (SNPHY) is currently trading at $13.90, 17% below its 52-week high. The current dividend yield is 1.38% based on an annual payout of $0.19 per share.
SNPHY (Santen Pharmaceutical Co., Ltd.) — 1.38% Dividend Yield Analysis
Santen Pharmaceutical Co., Ltd. (SNPHY) is a healthcare stock currently trading at $13.90 with a dividend yield of 1.38%. The company pays an annual dividend of $0.19 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, SNPHY has grown its dividend at a compound annual rate of 46.1%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.